跳转至内容
Merck
CN
  • Case management reduces global vascular risk after stroke: secondary results from the The preventing recurrent vascular events and neurological worsening through intensive organized case-management randomized controlled trial.

Case management reduces global vascular risk after stroke: secondary results from the The preventing recurrent vascular events and neurological worsening through intensive organized case-management randomized controlled trial.

American heart journal (2014-12-03)
Finlay A McAlister, Steven Grover, Raj S Padwal, Erik Youngson, Miriam Fradette, Ann Thompson, Brian Buck, Naeem Dean, Ross T Tsuyuki, Ashfaq Shuaib, Sumit R Majumdar
摘要

Survivors of ischemic stroke/transient ischemic attack (TIA) are at high risk for other vascular events. We evaluated the impact of 2 types of case management (hard touch with pharmacist or soft touch with nurse) added to usual care on global vascular risk. This is a prespecified secondary analysis of a 6-month trial conducted in outpatients with recent stroke/TIA who received usual care and were randomized to additional monthly visits with either nurse case managers (who counseled patients, monitored risk factors, and communicated results to primary care physicians) or pharmacist case managers (who were also able to independently prescribe according to treatment algorithms). The Framingham Risk Score [FRS]) and the Cardiovascular Disease Life Expectancy Model (CDLEM) were used to estimate 10-year risk of any vascular event at baseline, 6 months (trial conclusion), and 12 months (6 months after last trial visit). Mean age of the 275 evaluable patients was 67.6 years. Both study arms were well balanced at baseline and exhibited reductions in absolute global vascular risk estimates at 6 months: median 4.8% (Interquartile range (IQR) 0.3%-11.3%) for the pharmacist arm versus 5.1% (IQR 1.9%-12.5%) for the nurse arm on the FRS (P = .44 between arms) and median 10.0% (0.1%-31.6%) versus 12.5% (2.1%-30.5%) on the CDLEM (P = .37). These reductions persisted at 12 months: median 6.4% (1.2%-11.6%) versus 5.5% (2.0%-12.0%) for the FRS (P = .83) and median 8.4% (0.1%-28.3%) versus 13.1% (1.6%-31.6%) on the CDLEM (P = .20). Case management by nonphysician providers is associated with improved global vascular risk in patients with recent stroke/TIA. Reductions achieved during the active phase of the trial persisted after trial conclusion.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
胆固醇, Sigma Grade, ≥99%
Sigma-Aldrich
胆固醇, powder, BioReagent, suitable for cell culture, ≥99%
Sigma-Aldrich
SyntheChol ® NS0 补充, 500 ×, synthetic cholesterol, animal component-free, aqueous solution, sterile-filtered, suitable for cell culture
Sigma-Aldrich
胆固醇, from sheep wool, ≥92.5% (GC), powder
Supelco
胆固醇, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
胆固醇 溶液, certified reference material, 10 mg/mL in chloroform
SAFC
胆固醇, from sheep wool, Controlled origin, meets USP/NF testing specifications
Sigma-Aldrich
胆固醇, tested according to Ph. Eur.